Protein / target
Vascular endothelial growth factor A, long form
Protein at a glance
Biological role
Vascular endothelial growth factor receptor 1 binding
Primary system
Cardiovascular system
Strongest disease association
diabetic retinopathy
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
8 approved · 6 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity)
Subcellular location
Domains and Gene Ontology detail (127)Hide
Gene Ontology
- Cadherens junction
- Ccell surface
- Ccytoplasm
- Cendoplasmic reticulum
- Cextracellular matrix
- Cextracellular region
- Cextracellular space
- CGolgi apparatus
- Cmembrane
- Cnucleus
- Cplatelet alpha granule lumen
- Csecretory granule
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·cytokine activity
- ·positive regulation of mast cell chemotaxis
- ·positive regulation of trophoblast cell migration
- ·Interleukin-4 and Interleukin-13 signaling
Cell adhesion
- ·Secreted, extracellular space, extracellular matrix
- ·extracellular matrix
- ·extracellular matrix binding
- ·negative regulation of cell-cell adhesion mediated by cadherin
Transcriptional regulation
- ·negative regulation of gene expression
- ·negative regulation of miRNA transcription
- ·negative regulation of transcription by RNA polymerase II
- ·positive regulation of gene expression
Haemostasis
- ·platelet alpha granule lumen
- ·platelet-derived growth factor receptor binding
- ·positive regulation of cell proliferation by VEGF-activated platelet derived growth fact…
- ·Platelet degranulation
Kinase signalling
- ·positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- ·positive regulation of protein autophosphorylation
- ·positive regulation of protein phosphorylation
G protein-coupled signalling
- ·phospholipase C-activating G protein-coupled receptor signaling pathway
View underlying pathways (10)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Vascular endothelial growth factor A inhibitor
Appears in clinical studies involving macular degeneration, retinal vein occlusion, colorectal cancer, choroidal neovascularization
Vascular endothelial growth factor A inhibitor
Appears in clinical studies involving diabetic macular edema, wet macular degeneration, macular retinal edema, wet macular degeneration
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 6,064 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 14 total
wet macular degeneration
diabetic macular edema · wet macular degeneration · macular retinal edema
age-related macular degeneration
colorectal cancer · metastatic colorectal cancer · hepatocellular carcinoma
hepatocellular carcinoma · liver cancer · prostate cancer
macular degeneration · hereditary hemorrhagic telangiectasia · macular retinal edema
colorectal cancer · non-small cell squamous lung carcinoma · breast cancer
wet macular degeneration · macular degeneration · wet macular degeneration
ocular vascular disorder · age-related macular degeneration · wet macular degeneration
macular degeneration · retinal vein occlusion · colorectal cancer
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Clinical trial activityOllin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet
- New publicationAqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study.
- New publicationFour-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial.
- Regulatory approval
Approval: Eyluxvi (EMA)
- Regulatory approval
Approval: Mynzepli (EMA)
- Regulatory approval
Approval: Afiveg (EMA)
- Regulatory approval
Approval: Vgenfli (EMA)
- Regulatory approval
Approval: Eiyzey (EMA)
- Regulatory approval
Approval: Eydenzelt (EMA)
- Regulatory approval
Approval: Baiama (EMA)
- Regulatory approval
Approval: Ahzantive (EMA)
- Regulatory approval
Approval: Afqlir (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.